ODAC embraces GSK sarcoma drug, but Merck-Ariad med whacked
This article was originally published in Scrip
Executive Summary
While the US FDA's Oncologic Drugs Advisory Committee (ODAC) said GlaxoSmithKline's studies supported a favourable risk-benefit profile for Votrient (pazopanib) as a sarcoma treatment, the panel turned up its nose at Merck's and Ariad's ridaforolimus as a maintenance therapy for patients with the disease.